# MUC16

## Overview
MUC16 is a gene that encodes the protein mucin 16, a large transmembrane mucin primarily known for its role in epithelial barrier function and its association with cancer. Mucin 16, also referred to as CA125, is characterized by its extensive glycosylation and large molecular size, which contribute to its protective barrier properties on epithelial surfaces such as the ocular surface, respiratory tract, and reproductive system. The protein's structure includes a heavily O-glycosylated N-terminal subunit, multiple tandem repeats, and a transmembrane region with a cytoplasmic tail, which are crucial for its function in maintaining epithelial integrity and preventing pathogen invasion. Beyond its physiological roles, mucin 16 is implicated in cancer biology, particularly in ovarian cancer, where it facilitates metastasis and immune evasion through interactions with proteins like mesothelin and Siglec-9. These interactions, along with its role as a biomarker, underscore the clinical significance of MUC16 in cancer diagnosis and therapy (Hattrup2008Structure; Das2015Understanding; Gipson2014Comparison).

## Structure
MUC16 is a large transmembrane mucin characterized by a complex molecular structure. It has a core protein composed of 22,152 amino acids, with a molecular mass of 2.5 MDa, and a potential glycosylated mass of approximately 20 MDa (Hattrup2008Structure). The protein features a heavily O-glycosylated N-terminal subunit and a C-terminal portion that includes more than 60 tandem repeats of 156 amino acids, a transmembrane region, and a 32-residue cytoplasmic tail with potential phosphorylation sites (Hattrup2008Structure). 

MUC16 contains 16 SEA (Sperm protein, Enterokinase, Agrin) domains, which are structural modules characterized by an α/β sandwich fold composed of two α helices and four antiparallel β strands (Maeda2004Solution). The second SEA domain resembles those found in other mucins like MUC1 and may provide a site for proteolytic cleavage (Hattrup2008Structure). 

The extensive glycosylation of MUC16, including both O-glycans and N-glycans, contributes significantly to its structure and function. The carbohydrate content accounts for up to 77% of its weight, with N-glycans playing a crucial role in stability and barrier function (Taniguchi2017NGlycosylation). MUC16 also exhibits multiple splice variant isoforms, adding to its structural diversity (Maeda2004Solution).

## Function
MUC16, a transmembrane mucin, plays a critical role in maintaining epithelial barrier function in healthy human cells. It is predominantly active on mucosal surfaces such as the ocular surface, respiratory tract, and reproductive system. MUC16 contributes to the integrity of the epithelial barrier by preventing the penetration of pathogens and environmental particulates. Its large size and heavy O-glycosylation enhance its barrier properties, creating a robust protective layer on epithelial surfaces (Gipson2014Comparison).

MUC16 is involved in tight junction formation and transepithelial electrical resistance, crucial for maintaining barrier integrity. Knockdown studies have shown that reducing MUC16 expression disrupts the localization of tight junction proteins and decreases transepithelial resistance, indicating compromised barrier function (Gipson2014Comparison). MUC16 also prevents bacterial adherence and invasion, further supporting its role in epithelial defense (Gipson2014Comparison).

The mucin's extensive glycosylation provides antiadhesive properties, forming a hydrophilic environment that repels bacteria and prevents pathogen access to the epithelium (Hattrup2008Structure). MUC16's interaction with the actin cytoskeleton through its ERM-binding domain helps maintain the structure of the cell surface, contributing to its barrier function (Gipson2014Comparison).

## Clinical Significance
MUC16, also known as CA125, is a significant biomarker in various cancers, particularly ovarian cancer. Mutations and alterations in MUC16 expression are associated with several malignancies. In endometrial cancer, MUC16 mutations enhance antitumor immune responses, leading to improved patient prognosis. These mutations are linked to increased infiltration of cytotoxic T lymphocytes, which are crucial for antitumor immunity (Hu2018MUC16).

In ovarian cancer, MUC16 is involved in promoting metastasis through its interaction with mesothelin, facilitating tumor cell adhesion and spread. The cleavage of MUC16, particularly its carboxy-terminal domain, contributes to tumor cell migration and invasion, enhancing metastatic potential (Giamougiannis2021The; Thériault2011MUC16).

MUC16 is also implicated in pancreatic cancer, where its upregulation is associated with disease progression and metastasis. It is not expressed in normal pancreatic tissues but is significantly elevated in pancreatic cancer, suggesting its role in tumorigenesis (Haridas2011Pathobiological).

In gastric cancer, MUC16 mutations are linked to a better clinical outcome, as they are associated with decreased glycolytic capacity and reduced tumor growth (Zhao2018MUC16). These findings highlight the diverse roles of MUC16 in cancer progression and its potential as a therapeutic target.

## Interactions
MUC16, also known as CA125, is involved in several significant protein interactions that contribute to its role in cancer progression. It interacts with mesothelin, a glycosylphosphatidylinositol-linked cell surface protein, facilitating cell-cell adhesion and promoting metastasis, particularly in ovarian cancer. This interaction is dependent on the N-glycosylation of MUC16, and antibodies targeting the MUC16 tandem repeat region can disrupt this binding (Senapati2010Mucininteracting).

MUC16 also interacts with immune cell receptors such as Siglec-9, which inhibits immune cell cytotoxicity, aiding in immune evasion (Das2015Understanding). It forms complexes with Galectin-3 and the epidermal growth factor receptor (EGFR), stabilizing EGFR on the cell surface and enhancing signal transduction, which is crucial for cancer cell invasion (Rao2017Antibodies). The interaction with Galectin-3 is mediated by specific N-glycosylation sites on MUC16, which are critical for its oncogenic properties (Rao2017Antibodies).

Additionally, MUC16 interacts with JAK2, leading to increased proliferation and cancer stem cell phenotypes through STAT-dependent and independent pathways (Das2015Understanding). These interactions highlight the multifaceted role of MUC16 in cancer biology and its potential as a therapeutic target.


## References


[1. (Maeda2004Solution) Takeshi Maeda, Makoto Inoue, Seizo Koshiba, Takashi Yabuki, Masaaki Aoki, Emi Nunokawa, Eiko Seki, Takayoshi Matsuda, Yoko Motoda, Atsuo Kobayashi, Fumiko Hiroyasu, Mikako Shirouzu, Takaho Terada, Nobuhiro Hayami, Yoshiko Ishizuka, Naoko Shinya, Ayako Tatsuguchi, Mayumi Yoshida, Hiroshi Hirota, Yo Matsuo, Kazutoshi Tani, Takahiro Arakawa, Piero Carninci, Jun Kawai, Yoshihide Hayashizaki, Takanori Kigawa, and Shigeyuki Yokoyama. Solution structure of the sea domain from the murine homologue of ovarian cancer antigen ca125 (muc16). Journal of Biological Chemistry, 279(13):13174–13182, March 2004. URL: http://dx.doi.org/10.1074/jbc.M309417200, doi:10.1074/jbc.m309417200. This article has 123 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M309417200)

[2. (Gipson2014Comparison) Ilene K. Gipson, Sandra Spurr-Michaud, Ann Tisdale, and Balaraj B. Menon. Comparison of the transmembrane mucins muc1 and muc16 in epithelial barrier function. PLoS ONE, 9(6):e100393, June 2014. URL: http://dx.doi.org/10.1371/journal.pone.0100393, doi:10.1371/journal.pone.0100393. This article has 104 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0100393)

[3. (Haridas2011Pathobiological) Dhanya Haridas, Subhankar Chakraborty, Moorthy P. Ponnusamy, Imayavaramban Lakshmanan, Satyanarayana Rachagani, Eric Cruz, Sushil Kumar, Srustidhar Das, Subodh M. Lele, Judy M. Anderson, Uwe A. Wittel, Michael A. Hollingsworth, and Surinder K. Batra. Pathobiological implications of muc16 expression in pancreatic cancer. PLoS ONE, 6(10):e26839, October 2011. URL: http://dx.doi.org/10.1371/journal.pone.0026839, doi:10.1371/journal.pone.0026839. This article has 99 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0026839)

[4. (Hattrup2008Structure) Christine L. Hattrup and Sandra J. Gendler. Structure and function of the cell surface (tethered) mucins. Annual Review of Physiology, 70(1):431–457, March 2008. URL: http://dx.doi.org/10.1146/annurev.physiol.70.113006.100659, doi:10.1146/annurev.physiol.70.113006.100659. This article has 611 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1146/annurev.physiol.70.113006.100659)

[5. (Das2015Understanding) Srustidhar Das and Surinder K. Batra. Understanding the unique attributes of muc16 (ca125): potential implications in targeted therapy. Cancer Research, 75(22):4669–4674, November 2015. URL: http://dx.doi.org/10.1158/0008-5472.CAN-15-1050, doi:10.1158/0008-5472.can-15-1050. This article has 119 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.CAN-15-1050)

[6. (Hu2018MUC16) Jing Hu and Jing Sun. Muc16 mutations improve patients’ prognosis by enhancing the infiltration and antitumor immunity of cytotoxic t lymphocytes in the endometrial cancer microenvironment. OncoImmunology, 7(10):e1487914, August 2018. URL: http://dx.doi.org/10.1080/2162402X.2018.1487914, doi:10.1080/2162402x.2018.1487914. This article has 40 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1080/2162402X.2018.1487914)

[7. (Zhao2018MUC16) Huijin Zhao and Lan Zhang. Muc16 mutation predicts a favorable clinical outcome and correlates decreased warburg effect in gastric cancer. Biochemical and Biophysical Research Communications, 506(4):780–786, December 2018. URL: http://dx.doi.org/10.1016/j.bbrc.2018.10.156, doi:10.1016/j.bbrc.2018.10.156. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2018.10.156)

[8. (Senapati2010Mucininteracting) Shantibhusan Senapati, Srustidhar Das, and Surinder K. Batra. Mucin-interacting proteins: from function to therapeutics. Trends in Biochemical Sciences, 35(4):236–245, April 2010. URL: http://dx.doi.org/10.1016/j.tibs.2009.10.003, doi:10.1016/j.tibs.2009.10.003. This article has 124 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.tibs.2009.10.003)

[9. (Giamougiannis2021The) Panagiotis Giamougiannis, Pierre L Martin-Hirsch, and Francis L Martin. The evolving role of muc16 (ca125) in the transformation of ovarian cells and the progression of neoplasia. Carcinogenesis, 42(3):327–343, February 2021. URL: http://dx.doi.org/10.1093/carcin/bgab010, doi:10.1093/carcin/bgab010. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/carcin/bgab010)

[10. (Thériault2011MUC16) Catherine Thériault, Maxime Pinard, Marina Comamala, Martine Migneault, Julie Beaudin, Isabelle Matte, Marianne Boivin, Alain Piché, and Claudine Rancourt. Muc16 (ca125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecologic Oncology, 121(3):434–443, June 2011. URL: http://dx.doi.org/10.1016/j.ygyno.2011.02.020, doi:10.1016/j.ygyno.2011.02.020. This article has 134 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.ygyno.2011.02.020)

[11. (Rao2017Antibodies) Thapi Dharma Rao, Alberto Fernández-Tejada, Abram Axelrod, Nestor Rosales, Xiujun Yan, Sahityasri Thapi, Amy Wang, Kay J. Park, Brandon Nemieboka, Jingyi Xiang, Jason S. Lewis, Narciso Olvera, Douglas A. Levine, Samuel J. Danishefsky, and David R. Spriggs. Antibodies against specific muc16 glycosylation sites inhibit ovarian cancer growth. ACS Chemical Biology, 12(8):2085–2096, June 2017. URL: http://dx.doi.org/10.1021/acschembio.7b00305, doi:10.1021/acschembio.7b00305. This article has 30 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1021/acschembio.7b00305)

[12. (Taniguchi2017NGlycosylation) Takazumi Taniguchi, Ashley M. Woodward, Paula Magnelli, Nicole M. McColgan, Sylvain Lehoux, Sarah Melissa P. Jacobo, Jérôme Mauris, and Pablo Argüeso. N-glycosylation affects the stability and barrier function of the muc16 mucin. Journal of Biological Chemistry, 292(26):11079–11090, June 2017. URL: http://dx.doi.org/10.1074/jbc.m116.770123, doi:10.1074/jbc.m116.770123. This article has 58 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m116.770123)